AMO Pharma
London, United Kingdom· Est.
AMO Pharma is dedicated to making a positive difference for people affected by serious and debilitating diseases, particularly rare or orphan diseases.
Private Company
Total funding raised: $239M
About
AMO Pharma is dedicated to making a positive difference for people affected by serious and debilitating diseases, particularly rare or orphan diseases.
Small Molecules
Pipeline
55 drugs in pipeline2 in Phase 3
| Drug | Indication | Stage | Watch |
|---|---|---|---|
| Tideglusib + Placebo | Congenital Myotonic Dystrophy | Phase 2/3 | |
| Tideglusib | Congenital Myotonic Dystrophy | Phase 2/3 | |
| Tideglusib | Myotonic Dystrophy 1 | Phase 2 | |
| Tideglusib + Placebo | Arrhythmogenic Cardiomyopathy | Phase 2 | |
| Tideglusib | Congenital Myotonic Dystrophy | Pre-clinical |
Funding History
5Total raised:$239M
Series C$60M
Series B$60M
Series B$47M
Series A$47M